URGENT MEDICINE RECALL

Similar documents
NovoPen Echo URGENT MEDICAL DEVICE RECALL

GlucaGen HypoKit Glucagon (rys) hydrochloride

Package leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon

Urgent Notice September 16, 2014

URGENT: VOLUNTARY DRUG RECALL 07/05/2016

Urgent field safety notice

URGENT FIELD SAFETY NOTICE

Contacts Consumers:

URGENT FIELD SAFETY NOTICE

Manometer Tray, Jamshidi Needle Biopsy, Illinois (TJ) Needle Aspiration, Jamshidi (TJ) Needle Bone Marrow, Thoracentesis/Paracentesis Kit

Please read this leaflet carefully before you start to use Vagifem and keep it with your medicine. You may need to read it again.

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Please see the attached drug alert for onward transmission as below.

Product NDC Code Lot Number Expiry Dates Distribution Date VALSARTAN TABLETS 40MG 30CT

URGENT MEDICAL DEVICE CORRECTION. Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps

Before you use NovoThirteen. When NovoThirteen should not be used

pí=^åçêéïûë=eçìëé= oéöéåí=oç~ç= bçáåäìêöü=ben=pad= = = IMMEDIATE MESSAGE TO:

Temporary interruption in supply of APIDRA (insulin glulisine) - OPTISET and SOLOSTAR prefilled pens and CLIKSTAR reusable cartridges.

URGENT: DIETARY SUPPLEMENT RECALL

Urgent Medical Device Recall

Important Information about your 2.0 ml Animas Insulin Pump Cartridges

Changes to the National Diabetes Services Scheme (NDSS)

ADT Booster (ay-dee-tee boo-ster)

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

Medicines Optimisation Team Standard Operating Procedure Insulin Quantities Audit

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

Urgent field safety notice

URGENT FIELD SAFETY NOTICE: INSTRUCTIONS TO END USER

To ensure all education services at Mount Scopus Memorial College support students with diabetes.

Tuberculin PPD 100,000 units in 1 ml for Heaf Testing continues to be available.

If you have any questions, please contact Jerry Webb at ext or

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business

Urgent Field Corrective Action

UKALL14 DRUG SUPPLY GUIDELINES

URGENT FIELD SAFETY NOTICE Overconsumption following ElectroStatic Discharge or MRI scan

Guidelines for Product Recall or Withdrawal

Brown-Lupton Health Service Texas Christian University Campus P.O. Box Fort Worth, TX Dear Student,

PRODUCT RECALL NOTICE URGENT

ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME

Urgent Medical Device Correction

Darland High School Policy

Information Regarding Immunizations

Dear Prospective Volunteer:

New Zealand Datasheet

SOMATULINE LA 30mg Lanreotide

GLUCAGON ADMINISTRATION STUDENTS WITH TYPE 1 DIABETES DECEMBER

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

New Zealand Datasheet

FIELD SAFETY NOTICE (FSN) (Please refer to Annex 5 of the Guideline: MEDDEV REV.8 Guideline Vigilance)

medicines_management/correspondence/pathway-for-the-managed- Access-of-FreeStyle-Libre.

MERIEUX INACTIVATED RABIES VACCINE (MIRV)

NovoSeven RT 1.0mg, 2.0mg, 5.0mg and 8.0mg eptacog alfa (activated) (bhk) Consumer Medicine Information

URGENT FIELD SAFETY NOTICE/ DEVICE RECALL

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

Regulatory Operations. Insert size: ,5x dev Current 2.0. Colour: PMS 280C + PMS 648C + PMS 151C + PMS Green C + CMYK

MERIEUX INACTIVATED RABIES VACCINE (MIRV) Rabies Vaccine

Product Correction Urgent Immediate Action Required

TRAVELLING ndss.com.au AND TYPE 1 DIABETES

TRAVEL & TYPE 1 DIABETES ndss.com.au

PATIENT PREPAREDNESS PLAN

PANDEMIC (H1N1) 2009 VACCINATION INFORMATION & GUIDELINES

Suspected Defective Product Report

Application form for an Annual Practising Certificate 2017/2018 Application form for updating Practising Status 2017/2018 (Annual Renewal)

NovoRapid 10mL vial. What is in this leaflet. What NovoRapid is used for. Before you use. Insulin aspart (rys) Consumer Medicine Information

Access Points: Frequently Asked Questions 15 June 2016

Dear Friend of Union Academy,

1.0mg, 2.0mg, 5.0mg and 8.0mg

Artesunate 60 mg for injection WHOPAR part 5 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 LABELLING

DIRECTOR v NOVO NORDISK

NIIM HREC: TGA AUTHORISED PRESCRIBER SCHEME APPLICATION APPROVAL PROCEDURES 1. Procedures Statement

Volume 11; Number 5 February 2017 REVIEW OF GONADOTROPIN RELEASING HORMONE AGONISTS FOR PROSTATE CANCER (REVISED EDITION)

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

This leaflet answers some common questions about Cervagem.

Application form for an Annual Practising Certificate 2018/2019 Application form for updating Practising Status 2018/2019 (Annual Renewal)

Attachment 12 URGENT FIELD SAFETY REMOVAL FSCA3193. ETEST Ceftriaxone TXL32 (Ref , ) FOAM packaging

Australian Medicinal Cannabis Pricing Analysis

NovoRapid 10mL vial. What is in this leaflet. What NovoRapid is used for. Before you use. Insulin aspart (rys) Consumer Medicine Information

Menomune. Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined. Consumer Medicine Information

Guide for Storage of Insulin

NovoRapid Penfill. What is in this leaflet. Before you use. NovoRapid Penfill. What NovoRapid is used for. Insulin aspart (rys)

WELSH HEALTH CIRCULAR

~ Parent of Harmony Place Participant

PATIENT GROUP DIRECTION (PGD)

ORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies

REQUEST FOR PROPOSALS SUPPLY OF NICOTINE REPLACEMENT THERAPY

New regulatory requirements DPCS Regulations 2017

Injection Solution APP 100 mg/ml MULTI-DOSE IN 1VIAL, MULTI-DOSE / 20 ml IN 1 VIAL, MULTI-DOSE

MI Place Royal Luncheon

Colofac mebeverine hydrochloride

Medical gap arrangements - practitioner application

Contents. H1N1 09 swine influenza vaccine roll out. Who is eligible for the funded vaccine?

Public Health Dorset Prenoxad (Naloxone) Supply Standard Operating Procedure (SOP)

BEECHFIELD SCHOOL. Asthma Policy

Urgent Patient Notification

Mycamine Micafungin (as sodium)

Dosage of oseltamivir in children under 6 months of age in the swine flu pandemic

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging

Transcription:

Wednesday 7 th September 2016 URGENT MEDICINE RECALL GlucaGen HypoKit (glucagon (rys) as HCl 1 mg (1 IU) powder vial with 1 ml, prefilled solvent syringe); AUST R 47105 Batch numbers: FS6X465, FS6X536, FS6X715 & FS6X891 Expiry dates: All of the above batches have a shelf life expiry of August 2017 Important safety information for pharmacies in possession of GlucaGen HypoKit Dear Pharmacist-in-Charge, Novo Nordisk is recalling 4 batches of GlucaGen HypoKit in Australia. GlucaGen HypoKit is used for the Treatment of severe hypoglycaemic reactions which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. It is therefore important to have a functioning GlucaGen HypoKit that can be used effectively. Novo Nordisk conducted an investigation showing a small number of needles (0.006%) were detached from the pre-filled syringe supplied in certain batches of GlucaGen HypoKit. To protect patient safety Novo Nordisk is recalling all products in the affected batches from wholesalers, pharmacies and patients in Australia. The recalled GlucaGen HypoKit batch numbers and expiry dates are: Batch Number FS6X465 FS6X536 FS6X715 FS6X891 Expiry date The batch numbers are printed on the GlucaGen HypoKit as indicated below in the red box. Figure 1. A) GlucaGen HypoKit where the batch number is found in the red box, B) close up of the batch number Page 1 of 2

What to do if your pharmacy is in possession of a GlucaGen above-mentioned batch numbers HypoKit with one of the Please take the following action: 1. Please immediately quarantine all affected batches to prevent further distribution. 2. Please contact any patients you have supplied with a GlucaGen HypoKit and ask them to check the batch numbers on any product in their possession. Ask them to return any affected batches to you as soon as possible for exchange. These batches of GlucaGen HypoKit have been available to wholesalers since Feb 2016. Replacement stock of an unaffected batch is available. We suggest you estimate your replacement needs and obtain this now from your usual supplier so that you can replace recalled stock as it is returned to you. However in the event that you do NOT have stock from unaffected batches when a patient presents, please direct the patient to retain their current GlucaGen HypoKit from the affected batch until a replacement can be provided, as the likelihood of a detached needle is very low. In order to conserve stock and reduce possible future shortage, please do not return or accept for replacement any other batches than those listed above. Any patient returning a kit from another batch can be reassured about the quality of their GlucaGen HypoKit. Note that medical practitioners will also be contacted and requested to follow up with patients they have supplied since February 2016 and will be asked to return any stock they hold from affected batches. We have produced and enclosed a patient information leaflet you may find useful when explaining to patients the nature of the issue. You may wish to post this to customers you are unable to contact. The recalled stock should be forwarded to the wholesaler from which the product was purchased. All returned stock will be credited on receipt by your wholesaler. All recipients of this letter are requested to complete the accompanying Acknowledgement Form / Inventory of Returned Medicines (including nil stock if applicable) and return within 2 days of receipt by fax to (02) 8858 3697. If you have any questions regarding this recall, please contact NovoCare Customer Care Centre on 1800 668 626 for further information. This action has been undertaken following consultation with the Therapeutic Goods Administration (TGA). We sincerely regret the inconvenience caused by this action and assure you that Novo Nordisk takes this very seriously and has a rigorous quality assurance philosophy. Your support with this action is very much appreciated. Yours sincerely, Michala Fischer-Hansen Managing Director Novo Nordisk Australia & New Zealand Further information: NovoCare Customer Care Centre Phone: 1800 668 626 Email: aunrccc@novonordisk.com Page 2 of 2

ACKNOWLEDGEMENT FORM/ INVENTORY OF RETURNED MEDICINES Please complete and fax this form to (02) 8858 3697 within 2 days of receipt. Note: This form must be completed and returned even if no stock is held Product Batch No. No. of packs GlucaGen HypoKit FS6X465 GlucaGen HypoKit FS6X536 GlucaGen HypoKit FS6X715 GlucaGen HypoKit FS6X891 IF NO STOCK IS HELD, TICK THIS BOX Signature: Name: Position: Pharmacy name and address: Date: Page 1 of 1

PATIENT INFORMATION LETTER Wednesday 7 th September 2016 Important safety information for diabetes patients in possession of a GlucaGen HypoKit Novo Nordisk Pharmaceuticals Pty Ltd is recalling 4 batches of GlucaGen HypoKit in Australia. The GlucaGen HypoKit is indicated for the treatment of severe hypoglycaemic reactions which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. Novo Nordisk conducted an investigation showing a small number of needles (0.006 %) were detached from the pre-filled syringe supplied in certain batches of the GlucaGen HypoKit. To protect patient safety, Novo Nordisk is recalling all products in the affected batches from wholesalers, pharmacies and patients in Australia. The recalled GlucaGen HypoKit batch numbers and expiry date are: Batch no. FS6X465 FS6X536 FS6X715 FS6X891 Expiry date The batch numbers are printed on the GlucaGen HypoKit as indicated below in the red box Figure 1. A) GlucaGen HypoKit where the batch number is found in the red box, B) close-up of the batch number What to do if you are in possession of a GlucaGen HypoKit with one of the above-mentioned batch numbers: Return your GlucaGen HypoKit product with the above-mentioned batch numbers to your pharmacy. You will be given a free replacement GlucaGen HypoKit either immediately (if pharmacy stock is present) or within a few days (if pharmacy Page 1 of 2

needs to await re-supply). If you do not receive a replacement immediately, retain your GlucaGen HypoKit until the replacement can be provided, as the likelihood of a detached needle is very low. GlucaGen HypoKit is to be used for episodes of severe hypoglycaemia (low blood sugar) when you have become unconscious or are unable to ingest a source of sugar. It is therefore important that you have a functioning GlucaGen HypoKit that can be used effectively. Please check the batch number on your GlucaGen HypoKit and take action as recommended in this communication. Importantly, if you are in possession of a GlucaGen HypoKit product with a batch number NOT mentioned above there is no concern and you can be confident that the product will work as prescribed. If you have any questions regarding this recall, please contact NovoCare Customer Care Centre on 1800 668 626 for further information. This action has been undertaken following consultation with the Therapeutic Goods Administration (TGA). We sincerely regret the inconvenience caused by this action and assure you that Novo Nordisk takes this very seriously and has a rigorous quality assurance philosophy. Yours sincerely, Michala Fischer-Hansen Managing Director Novo Nordisk Australia & New Zealand Further information: NovoCare Customer Care Centre Phone: 1800 668 626 Email: aunrccc@novonordisk.com www.novonordisk.com.au Page 2 of 2